UCB Announces Phase 3 Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis (gMG)

Returning guest, Dr. Omar Sinno, MD, MBA, U.S. Medical Lead, Rare Disease at UCB discusses positive efficacy and safety results from two phase 3 studies evaluating zilucoplan, a self-administered, subcutaneous (SC) peptide inhibitor of complement component 5 (C5 inhibitor), and rozanolixizumab, an SC-infused monoclonal antibody targeting the neonatal Fc receptor (FcRn) in adults with generalized myasthenia gravis (gMG). UCB is currently the only company investigating two potential treatments with multiple mechanisms of action in gMG. These results were presented as posters at the 14th Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia and Related Disorders. Zilucoplan and rozanolixizumab are not approved for use in any indication by any regulatory authority worldwide.

Omar Sinno, MD, MBA, is the U.S. Medical Lead, Rare Disease at UCB. In this role, Dr. Sinno is responsible for providing strategic and executional leadership for the company’s growing presence in the rare neuromuscular disease space and commitment to improving awareness and care for people living with severe disease. He received his medical degree from the Loyola University Chicago Stritch School of Medicine and his MBA from the University of Chicago Booth School of Business. Prior to joining UCB, Omar served as Medical Director of AltaThera Pharmaceuticals in Chicago and as Chief Medical Officer of Unite Genomics in San Francisco.